Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07372625 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Name: A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. — clinical trial record (NCT07372625)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorPMV Pharmaceuticals, Inc

Started2026-02-04

View on ClinicalTrials.gov ↗

Amendment history

2026-08-11

Study Status, Contacts/Locations v2

Study sitescontacts updated at 5 of 5 sites

2026-03-10

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2026-01-19→confirmed 2026-02-04

Study sitesdetails revised at 5 of 5 sites

2026-01-20

Original filing

PMV Pharmaceuticals, Inc

2 trials monitored

See 1 trial at risk

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Trial Details

NCT Number	NCT07372625
Lead Sponsor	PMV Pharmaceuticals, Inc Collaborators: SCRI Development Innovations, LLC
Conditions	TP53 Y220C Mutation, Advanced Solid Tumors
Enrollment	14 participants
Start Date	2026-02-04
Primary Completion	2027-03 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-12